Kyphoplasty Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Balloon Catheters, Bone Access Devices, Cement Application Products, Bone Cement, Cement Mixing System, Instruments), By Application (Vertebral Alignment Restoration, Spinal Fractures, Kyphosis), By Indication (Osteoporosis, Others), By End User (Hospitals & Clinics, Ambulatory Surgical Centres, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 734.85 Million
CAGR (2026-2031)	6.51%
Fastest Growing Segment	Balloon Catheters
Largest Market	North America
Market Size (2031)	USD 1072.85 Million

Market Overview

The Global Kyphoplasty Market will grow from USD 734.85 Million in 2025 to USD 1072.85 Million by 2031 at a 6.51% CAGR. Kyphoplasty is a minimally invasive surgical procedure designed to treat vertebral compression fractures by inserting a specialized balloon into the fractured vertebra to restore height and create a cavity for bone cement stabilization. The primary drivers propelling the Global Kyphoplasty Market include the rapidly aging global population and the concurrent rise in osteoporosis prevalence, which significantly increases the incidence of spinal fractures requiring intervention. Furthermore, the growing preference for minimally invasive techniques over traditional open back surgeries supports market growth due to benefits such as reduced recovery times and shorter hospital stays.

Despite these positive factors, the market faces a significant challenge regarding stringent reimbursement policies and the high cost associated with these procedures, which can restrict patient access in cost-sensitive healthcare systems. According to the International Osteoporosis Foundation, in 2024, up to 37 million fragility fractures occur annually worldwide in individuals aged over 55. This substantial incidence rate highlights the urgent demand for effective fracture management solutions, yet economic barriers and coverage limitations remain a substantial impediment to broader market expansion.

Key Market Drivers

Technological innovations in kyphoplasty systems and bone cements are significantly accelerating market growth by enhancing procedural safety and clinical outcomes. Manufacturers are increasingly developing advanced balloon catheters and high-viscosity cements that minimize leakage risks and ensure precise vertebral height restoration, thereby boosting surgeon confidence and adoption rates. The integration of steerable balloons and radiofrequency-targeted vertebral augmentation has streamlined operative workflows, making these minimally invasive interventions more attractive than traditional surgical methods. This robust demand for advanced interventional solutions is evident in recent industry performance. According to Stryker, February 2025, in the 'Fourth Quarter and Full Year 2024 Operating Results' report, the company's Interventional Spine business, which houses its kyphoplasty portfolio, achieved organic sales growth exceeding 10% for the full year 2024, reflecting strong market uptake of its specialized spine technologies.

Concurrently, the rising prevalence of osteoporosis and vertebral compression fractures serves as a fundamental catalyst for the expansion of the global kyphoplasty market. As the global population ages, the incidence of low-bone-density conditions escalates, creating a substantial pool of patients susceptible to fragility fractures that require surgical stabilization. This demographic shift is creating an urgent clinical need for effective fracture management strategies. According to the U.S. Preventive Services Task Force, January 2025, in the 'Final Recommendation Statement on Screening for Osteoporosis', the prevalence of osteoporosis is significantly elevated in the aging demographic, affecting 27.1% of women aged 65 years or older. This high prevalence directly correlates with increased procedural volumes as healthcare providers prioritize early intervention to prevent cascading health complications. Indicating the broader financial health of the sector driven by this demand, according to Merit Medical Systems, in 2025, the company reported a total annual revenue of $1.357 billion for 2024, representing a 7.9% increase year-over-year, largely supported by its proprietary medical devices used in interventional procedures.

Download Free Sample Report

Key Market Challenges

Stringent reimbursement policies and high procedural costs constitute a substantial barrier to the expansion of the kyphoplasty market. Healthcare providers frequently encounter complex approval processes and declining payout rates for vertebral augmentation procedures, which discourages the widespread adoption of this treatment in cost-sensitive environments. When insurance coverage is denied or restricted, the financial liability often shifts to patients or medical facilities, leading to a reduction in elective procedure volumes. This economic pressure compels hospitals to prioritize conservative management options, such as bed rest and pain medication, over minimally invasive surgical interventions.

These financial constraints are intensifying across major healthcare systems, directly affecting the profitability and viability of offering such specialized surgeries. According to the American Medical Association, in 2024, Medicare physician payment rates were reduced by 3.39 percent, further compressing the operating margins for surgical practices performing procedures like kyphoplasty. Such fiscal tightening limits the ability of healthcare providers to invest in necessary equipment and reduces patient access to advanced spinal care. Consequently, valid clinical candidates for kyphoplasty are often diverted toward lower-cost therapies, directly impeding the total market revenue growth.

Key Market Trends

The Shift of Vertebral Augmentation Procedures to Ambulatory Surgical Centers (ASCs) represents a fundamental structural change driven by the demand for cost-efficient outpatient care. As kyphoplasty is minimally invasive, payers are actively migrating these cases from traditional hospitals to specialized facilities to reduce overhead costs and improve patient throughput. This migration is supported by the operational efficiency of ASCs, which allows for higher case volumes and expedited discharge processes. Highlighting the financial viability and expansion of this care setting, according to Surgery Partners, March 2025, in the 'Fourth Quarter and Full Year 2024 Results' report, the company achieved a total annual revenue of $3.1 billion for 2024, a 13.5% increase year-over-year, fueled by the strategic acquisition and development of short-stay surgical facilities.

Concurrently, the Incorporation of Intraoperative 3D Fluoroscopy and Navigation Technologies is redefining procedural standards by addressing the critical need for precision during cement delivery. Unlike standard 2D imaging, these advanced systems provide real-time, multi-dimensional visualization of the vertebral anatomy, significantly reducing the risk of cement leakage and lowering radiation exposure for the surgical team. This technological integration enhances clinical confidence in treating complex fractures, thereby encouraging broader utilization of augmentation therapies. According to Medtronic, February 2025, in the 'Third Quarter Fiscal Year 2025 Financial Results' press release, the Cranial and Spinal Technologies division reported revenue of $1.25 billion, a 3.8% increase year-over-year, primarily driven by the robust market adoption of its AiBLE ecosystem of enabling technologies.

Segmental Insights

The Balloon Catheters segment is recognized as the fastest-growing category within the Global Kyphoplasty Market, driven by the device's critical role in restoring vertebral body height. Unlike standard instruments, balloon catheters create a contained cavity for bone cement, which significantly mitigates the risk of cement leakage during procedures. This safety advantage aligns with increasing clearances from the U.S. Food and Drug Administration for modified catheter designs, thereby accelerating their adoption among healthcare providers seeking effective solutions for vertebral compression fractures.

Regional Insights

North America holds a leading position in the global kyphoplasty market, driven largely by the rising prevalence of osteoporosis and resulting vertebral compression fractures among the aging population. The region benefits from a well-established healthcare infrastructure and favorable reimbursement policies that increase patient access to minimally invasive spinal surgeries. Additionally, the presence of key medical device manufacturers, coupled with consistent product clearances from the U.S. Food and Drug Administration (FDA), accelerates the adoption of these treatments. High healthcare spending in the United States and Canada further solidifies the region’s market dominance.

Recent Developments

• In September 2025, Amber Implants announced that it had secured 510(k) clearance from the U.S. Food and Drug Administration for its VCFix Spinal System. This innovative vertebral augmentation device is designed to treat a wide range of vertebral compression fractures by providing robust support to both the anterior and posterior columns of the spine in conjunction with bone cement. The regulatory approval validated the safety and clinical performance of the system, paving the way for a commercial pilot launch in the United States planned for early 2026. This development positioned the company to introduce a differentiated solution that aims to improve spinal stabilization and patient recovery times in the global kyphoplasty market.
• In January 2025, Stryker Corporation announced a definitive agreement to divest its U.S. spinal implants business to Viscogliosi Brothers, LLC, which established a new independent entity named VB Spine, LLC. While this transaction transferred ownership of Stryker's portfolio of pedicle screws and interbody cages, the company explicitly retained its Interventional Spine business, which includes its comprehensive suite of vertebral augmentation and vertebroplasty solutions. This strategic realignment allowed Stryker to sharpen its focus on its high-growth interventional and enabling technology segments, reaffirming its commitment to the kyphoplasty market by keeping these specialized assets within its core operations while partnering with the new entity for future collaborations.
• In September 2024, Xelite Biomed received 510(k) clearance from the U.S. Food and Drug Administration for its XeliteMed VertehighFix High Viscosity Spinal Bone Cement. This newly approved product is specifically indicated for the fixation of pathological fractures of the vertebral body using vertebroplasty and kyphoplasty procedures. The regulatory clearance marked a significant milestone for the company, introducing a new high-viscosity cement option to the U.S. market. The product is designed to offer surgeons improved control during injection and minimize the risk of cement leakage, a critical safety factor in the minimally invasive treatment of osteoporotic compression fractures.
• In June 2024, Medtronic entered into a strategic partnership with Merit Medical Systems to expand its portfolio of treatments for vertebral compression fractures in the United States. Under the terms of the collaboration, Medtronic agreed to market and distribute a new unipedicular, steerable balloon catheter manufactured by Merit Medical. This agreement leveraged Merit Medical's expertise in manufacturing and regulatory compliance while utilizing Medtronic's extensive sales network to deliver advanced vertebral augmentation solutions to physicians. The partnership aimed to provide clinicians with greater flexibility and precision during kyphoplasty procedures, enhancing the ability to target specific areas within the vertebral body for optimal height restoration.

Key Market Players

• Stryker Corporation
• Medtronic plc
• Smith + Nephew Plc
• Microport Scientific Corporation
• DePuy Synthes Companies
• IZI Medical Products, LLC
• Merit Medical Systems, Inc.
• Joline GmbH & Co. KG
• Hensler Surgical Products LLC
• Jiangsu Changmei Medtech Co., Ltd.

By Product	By Application	By Indication	By End User	By Region
Balloon Catheters Bone Access Devices Cement Application Products Bone Cement Cement Mixing System Instruments	Vertebral Alignment Restoration Spinal Fractures Kyphosis	Osteoporosis Others	Hospitals & Clinics Ambulatory Surgical Centres Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Kyphoplasty Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Kyphoplasty Market, By Product:

• Balloon Catheters
• Bone Access Devices
• Cement Application Products
• Bone Cement
• Cement Mixing System
• Instruments

• Kyphoplasty Market, By Application:

• Vertebral Alignment Restoration
• Spinal Fractures
• Kyphosis

• Kyphoplasty Market, By Indication:

• Osteoporosis
• Others

• Kyphoplasty Market, By End User:

• Hospitals & Clinics
• Ambulatory Surgical Centres
• Others

• Kyphoplasty Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE